Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | SLC1A5 | Q15758 | 12/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838808 | 0.83 | ARG1 (0.50) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL13233388 | 0.83 | ARG1 (0.50) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL15501038 | 0.83 | ARG1 (0.50) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL13233376 | 0.82 | ARG1 (0.52) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL13233375 | 0.82 | ARG1 (0.49) | ARG1DPP8DPP9DPP7SLC1A5 | |
| SCHEMBL13263990 | 0.81 | ARG1 (0.51) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL2504723 | 0.79 | ARG1 (0.46) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL13233393 | 0.79 | ARG1 (0.46) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL2303123 | 0.78 | ARG1 (0.49) | ARG1DPP8DPP9DPP7CXCR4 | |
| SCHEMBL2303111 | 0.78 | ARG1 (0.49) | ARG1DPP8DPP9DPP7CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-8962799-B2 | Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8840865-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | ARG1 330/4885DPP8 3293/4885DPP9 4165/4885 |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | ARG1 170/4885DPP8 573/4885DPP9 1216/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | ARG1 330/4885DPP8 3293/4885DPP9 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.